334 related articles for article (PubMed ID: 1371291)
1. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
[TBL] [Abstract][Full Text] [Related]
2. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
[TBL] [Abstract][Full Text] [Related]
3. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia.
Beisland HO; Binkowitz B; Brekkan E; Ekman P; Kontturi M; Lehtonen T; Lundmo P; Pappas F; Round E; Shapiro D
Eur Urol; 1992; 22(4):271-7. PubMed ID: 1283370
[TBL] [Abstract][Full Text] [Related]
4. Finasteride for benign prostatic hyperplasia.
Hasinski S; Miller JL; Rose LI
Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
[TBL] [Abstract][Full Text] [Related]
5. Androgen metabolism in men receiving finasteride before prostatectomy.
Norman RW; Coakes KE; Wright AS; Rittmaster RS
J Urol; 1993 Nov; 150(5 Pt 2):1736-9. PubMed ID: 7692110
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
7. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group.
Stoner E
J Urol; 1992 May; 147(5):1298-302. PubMed ID: 1373779
[TBL] [Abstract][Full Text] [Related]
8. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
9. Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism.
Matzkin H; Chen J; Weisman Y; Goldray D; Pappas F; Jaccard N; Braf Z
Clin Endocrinol (Oxf); 1992 Nov; 37(5):432-6. PubMed ID: 1283117
[TBL] [Abstract][Full Text] [Related]
10. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency.
Imperato-McGinley J; Shackleton C; Orlic S; Stoner E
J Clin Endocrinol Metab; 1990 Mar; 70(3):777-82. PubMed ID: 1689740
[TBL] [Abstract][Full Text] [Related]
11. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
12. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
13. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group.
Prostate; 1993; 22(4):291-9. PubMed ID: 7684524
[TBL] [Abstract][Full Text] [Related]
14. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
Stoner E
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
[TBL] [Abstract][Full Text] [Related]
15. 5 alpha-metabolism in finasteride-treated subjects and male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. A review.
Imperato-McGinley J
Eur Urol; 1991; 20 Suppl 1():78-81. PubMed ID: 1722167
[TBL] [Abstract][Full Text] [Related]
16. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
Kirby RS; Vale J; Bryan J; Holmes K; Webb JA
Eur Urol; 1993; 24(1):20-6. PubMed ID: 7689971
[TBL] [Abstract][Full Text] [Related]
17. Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation.
Kirby RS; Bryan J; Eardley I; Christmas TJ; Liu S; Holmes SA; Vale JA; Shanmuganathan K; Webb JA
Br J Urol; 1992 Jul; 70(1):65-72. PubMed ID: 1379107
[TBL] [Abstract][Full Text] [Related]
18. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
J Androl; 1991; 12(6):372-5. PubMed ID: 1722792
[TBL] [Abstract][Full Text] [Related]
19. Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia.
Vermeulen A; Giagulli VA; De Schepper P; Buntinx A
Eur Urol; 1991; 20 Suppl 1():82-6. PubMed ID: 1722168
[TBL] [Abstract][Full Text] [Related]
20. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
